A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2015.04.005
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2015
Authors
Publisher
Elsevier BV